miR-4759 suppresses breast cancer through immune checkpoint blockade

Autor: You-Zhe Lin, Shu-Hsuan Liu, Wan-Rong Wu, Yi-Chun Shen, Yuan-Liang Wang, Chien-Ching Liao, Pei-Le Lin, Han Chang, Liang-Chih Liu, Wei-Chung Cheng, Shao-Chun Wang

Publikováno v: Computational and Structural Biotechnology Journal, Vol 20, Iss , Pp 241-251 (2022)

Programmed cell death protein 1 (PD-1)/ programmed cell death protein ligand 1 (PD-L1) is the key immune checkpoint governing evasion of advanced cancer from immune surveillance. Immuno-oncology (IO) therapy targeting PD-1/PD-L1 with traditional anti

Externí odkaz: https://doaj.org/article/423d23f17e274b99b22b9109a1cabf8b

miR-4759 suppresses breast cancer through immune checkpoint blockade.

Autor: Lin YZ; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan., Liu SH; Research Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan., Wu WR; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan., Shen YC; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan., Wang YL; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan.; Center for Molecular Medicine, China Medical University Hospital, Taichung 40447, Taiwan., Liao CC; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan., Lin PL; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan., Chang H; Division of Molecular Pathology, Department of Pathology, China Medical University Hospital, Taichung 40447, Taiwan., Liu LC; Department of Surgery, China Medical University Hospital, Taichung 40447, Taiwan., Cheng WC; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan.; Research Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan.; Cancer Biology and Drug Discovery Ph.D. Program, China Medical University, Taichung 40402, Taiwan., Wang SC; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan.; Center for Molecular Medicine, China Medical University Hospital, Taichung 40447, Taiwan.; Center for Molecular Medicine, China Medical University Hospital, Taichung 40447, Taiwan.; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA.; Cancer Biology and Drug Discovery Ph.D. Program, China Medical University, Taichung 40402, Taiwan.; Department of Biotechnology, Asia University, Taichung 41354, Taiwan.

Publikováno v: Computational and structural biotechnology journal [Comput Struct Biotechnol J] 2021 Dec 16; Vol. 20, pp. 241-251. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2022).

Mechanism research of non‐coding RNA in immune checkpoint inhibitors therapy.

Autor: Bian, Jie, Shao, Rui, Li, Juan, Zhu, Jing‐Feng, Shao, Ai‐Zhong, Liu, Chao, Lu, L. V., Pan, Hui‐Wen, Shi, Yi‐Jun, Fang, Na

Publikováno v: Cancer Science; Nov2024, Vol. 115 Issue 11, p3520-3531, 12p

Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties.

Autor: Hu T; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Shi R; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Gu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Zhou H; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Oncology, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China., Fang Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Xu T; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Oncology, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China., Xu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Wu X; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Ma L; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Oncology, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China., Shu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Oncology, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.

Publikováno v: Wiley interdisciplinary reviews. RNA [Wiley Interdiscip Rev RNA] 2023 Oct 10, pp. e1822. Date of Electronic Publication: 2023 Oct 10.